PT - JOURNAL ARTICLE AU - Goscé, Lara AU - Tadesse, Amare Worku AU - Foster, Nicola AU - Van Kalmthout, Kristian AU - van Rest, Job AU - .vanderwal, jense AU - Harker, Martin AU - Madden, Norma AU - Abdurhman, Tofik AU - Gadissa, Demekech AU - Bedru, Ahmed AU - Dube, Tanyaradzwa Nicolette AU - Alacapa, Jason AU - Mganga, Andrew AU - Deyanova, Natasha AU - Charalambous, Salome AU - Letta, Taye AU - Jerene, Degu AU - White, Richard AU - Fielding, Katherine AU - Houben, Rein M G J AU - McQuaid, Christopher Finn TI - Modelling the epidemiological and economic impact of digital adherence technologies with differentiated care for tuberculosis treatment in Ethiopia AID - 10.1101/2024.07.30.24310024 DP - 2024 Jan 01 TA - medRxiv PG - 2024.07.30.24310024 4099 - http://medrxiv.org/content/early/2024/08/01/2024.07.30.24310024.short 4100 - http://medrxiv.org/content/early/2024/08/01/2024.07.30.24310024.full AB - Background Digital adherence technologies (DATs) with associated differentiated care are potential tools to improve tuberculosis (TB) treatment outcomes and reduce associated costs for both patient and healthcare providers. However, the balance between epidemiological and economic benefits remains unclear. Here, we used data from a large trial (PACTR202008776694999) to estimate the potential long – term epidemiological and economic impact of DAT interventions in Ethiopia. Methods We developed a compartmental transmission model for TB, calibrated to Ethiopia and parameterised with patient and provider costs. We compared the epidemiological and economic impact of two DAT interventions, a digital pillbox and medication labels, to the current standard of care, assuming each was introduced at scale in 2023. We projected long – term TB incidence, mortality and costs to 2035, and conducted a threshold analysis to identify the maximum possible epidemiological impact of a DAT intervention by assuming 100% treatment completion for patients on DAT. Findings We estimated small and uncertain epidemiological benefits of the pillbox intervention compared to the standard of care in Ethiopia, with a difference of – 0.4% ( – 1.1; +2.0) incident TB episodes and – 0.7% (– 2.2; +3.6) TB deaths. However, our analysis also found large total provider and patient cost savings [$163 ($118; $211) and $3 ($1; $5) million respectively over 2023 – 2035], translating to a 50.2% (35.9%; 65.2%) reduction in total cost of treatment. Results were similar for the medication label intervention. The maximum possible epidemiological impact a theoretical DAT intervention could achieve over the same timescale would be a 3% (1.4; 5.5%) reduction in incident TB and a 8.2% (4.4; 12.8) reduction in TB deaths. Interpretation DAT interventions, while showing limited epidemiological impact, could substantially reduce TB treatment costs for both patients and the healthcare provider.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by UNITAIDAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript